Progressive macular hypomelanosis among Egyptian patients: a clinicopathological study

Background: Progressive macular hypomelanosis (PMH) is a disease of unclear etiology. Propionbacterium acnes (P. acnes) was claimed to be an etiological factor. Objectives: The purpose of this study was to document the clinicopathological features of PMH in Egyptian patients and to evaluate the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mohamed Khaled Selim, El-Shahat Farag Ahmed, Mamdouh Morsy Abdelgawad, Mohammed Fawzy El-Kamel
Formato: article
Lenguaje:EN
Publicado: Mattioli1885 2011
Materias:
Acceso en línea:https://doaj.org/article/7521e17f9a1442c3958c49b08ef2d2ec
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7521e17f9a1442c3958c49b08ef2d2ec
record_format dspace
spelling oai:doaj.org-article:7521e17f9a1442c3958c49b08ef2d2ec2021-11-17T08:33:25ZProgressive macular hypomelanosis among Egyptian patients: a clinicopathological study10.5826/dpc.0101a032160-9381https://doaj.org/article/7521e17f9a1442c3958c49b08ef2d2ec2011-10-01T00:00:00Zhttp://dpcj.org/index.php/dpc/article/view/999https://doaj.org/toc/2160-9381 Background: Progressive macular hypomelanosis (PMH) is a disease of unclear etiology. Propionbacterium acnes (P. acnes) was claimed to be an etiological factor. Objectives: The purpose of this study was to document the clinicopathological features of PMH in Egyptian patients and to evaluate the therapeutic outcome. Methods: Patients with clinical features of PMH were recruited. Wood’s lamp examination, skin scrapings for fungi, and skin biopsy specimens were obtained. Biopsies were stained with hematoxylin and eosin, PAS, Fontana-Masson, and S100 protein. Patients received either narrow-band UVB (nbUVB) or nbUVB plus daily topical clindamycin 1% and benzoyl peroxide gel 5% (bcUVB). The period of active treatment was 14 weeks followed by a follow-up period of 24 weeks. Results: Twenty-nine patients were included. Microscopic evaluation of skin biopsy specimens showed no significant differences between lesional and normal skin. Fontana-Masson stained sections showed overall reduction of melanin granules in the basal layer of lesional skin only and S100 staining did not detect significant differences in the number of melanocytes in lesional and normal skin. Nearly complete repigmentation was reported in 10 patients treated with bcUVB compared to 9 patients treated with nbUVb with no significant differences between both groups after 14 weeks. Only 2 patients in each group retained the pigmentation and the remaining patients returned to the baseline color before treatment. Conclusions: This study documented the clinicopathological features of PMH among Egyptians. No permanently effective treatment is available. Further studies are needed to prove or disprove the pathogenic role of P. acnes in PMH. Mohamed Khaled SelimEl-Shahat Farag AhmedMamdouh Morsy AbdelgawadMohammed Fawzy El-KamelMattioli1885articleprogressive macular hypomelanosisDermatologyRL1-803ENDermatology Practical & Conceptual (2011)
institution DOAJ
collection DOAJ
language EN
topic progressive macular hypomelanosis
Dermatology
RL1-803
spellingShingle progressive macular hypomelanosis
Dermatology
RL1-803
Mohamed Khaled Selim
El-Shahat Farag Ahmed
Mamdouh Morsy Abdelgawad
Mohammed Fawzy El-Kamel
Progressive macular hypomelanosis among Egyptian patients: a clinicopathological study
description Background: Progressive macular hypomelanosis (PMH) is a disease of unclear etiology. Propionbacterium acnes (P. acnes) was claimed to be an etiological factor. Objectives: The purpose of this study was to document the clinicopathological features of PMH in Egyptian patients and to evaluate the therapeutic outcome. Methods: Patients with clinical features of PMH were recruited. Wood’s lamp examination, skin scrapings for fungi, and skin biopsy specimens were obtained. Biopsies were stained with hematoxylin and eosin, PAS, Fontana-Masson, and S100 protein. Patients received either narrow-band UVB (nbUVB) or nbUVB plus daily topical clindamycin 1% and benzoyl peroxide gel 5% (bcUVB). The period of active treatment was 14 weeks followed by a follow-up period of 24 weeks. Results: Twenty-nine patients were included. Microscopic evaluation of skin biopsy specimens showed no significant differences between lesional and normal skin. Fontana-Masson stained sections showed overall reduction of melanin granules in the basal layer of lesional skin only and S100 staining did not detect significant differences in the number of melanocytes in lesional and normal skin. Nearly complete repigmentation was reported in 10 patients treated with bcUVB compared to 9 patients treated with nbUVb with no significant differences between both groups after 14 weeks. Only 2 patients in each group retained the pigmentation and the remaining patients returned to the baseline color before treatment. Conclusions: This study documented the clinicopathological features of PMH among Egyptians. No permanently effective treatment is available. Further studies are needed to prove or disprove the pathogenic role of P. acnes in PMH.
format article
author Mohamed Khaled Selim
El-Shahat Farag Ahmed
Mamdouh Morsy Abdelgawad
Mohammed Fawzy El-Kamel
author_facet Mohamed Khaled Selim
El-Shahat Farag Ahmed
Mamdouh Morsy Abdelgawad
Mohammed Fawzy El-Kamel
author_sort Mohamed Khaled Selim
title Progressive macular hypomelanosis among Egyptian patients: a clinicopathological study
title_short Progressive macular hypomelanosis among Egyptian patients: a clinicopathological study
title_full Progressive macular hypomelanosis among Egyptian patients: a clinicopathological study
title_fullStr Progressive macular hypomelanosis among Egyptian patients: a clinicopathological study
title_full_unstemmed Progressive macular hypomelanosis among Egyptian patients: a clinicopathological study
title_sort progressive macular hypomelanosis among egyptian patients: a clinicopathological study
publisher Mattioli1885
publishDate 2011
url https://doaj.org/article/7521e17f9a1442c3958c49b08ef2d2ec
work_keys_str_mv AT mohamedkhaledselim progressivemacularhypomelanosisamongegyptianpatientsaclinicopathologicalstudy
AT elshahatfaragahmed progressivemacularhypomelanosisamongegyptianpatientsaclinicopathologicalstudy
AT mamdouhmorsyabdelgawad progressivemacularhypomelanosisamongegyptianpatientsaclinicopathologicalstudy
AT mohammedfawzyelkamel progressivemacularhypomelanosisamongegyptianpatientsaclinicopathologicalstudy
_version_ 1718425678533099520